MONOCLONAL ANTI FCR ANTIBODY TREATMENT OF REFRACTORY ITP
抗FCR单克隆抗体治疗难治性ITP
基本信息
- 批准号:3354832
- 负责人:
- 金额:$ 12.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-04-01 至 1991-03-31
- 项目状态:已结题
- 来源:
- 关键词:antiantibody antibody formation antibody receptor antiidiotype antibody antireceptor antibody autoantibody autoimmune disorder blocking antibody blood cell count dosage enzyme linked immunosorbent assay gel electrophoresis human subject immunofluorescence technique immunohematology immunomodulators immunoregulation immunotherapy monoclonal antibody opsonin plaque assay platelets radiotracer reticuloendothelial system splenectomy therapy compliance thrombocytopenia thrombocytopenic purpura
项目摘要
3G8 is a mouse monoclonal anti Fc receptor antibody which
recognizes and blocks the active site of FcRp52-70, an FcR found
on granulocytes, tissue macrophages, and large granular
lymphocytes. MPS FcR blockade with another mouse monoclonal
anti FcR antibody (24G2) has been shown to decrease clearance of
immune complexes in mice. Our studies in chimpanzees showed
that infusion of 3G8 substantially slowed clearance of opsonized
red cells. Clinical studies with intravenous gammaglobulin (IVGG)
has suggested that MPS FcR blockade could underlie therapeutic
responses in autoimmune thrombocytopenic purpura, a severe
bleeding disorder in which profound thrombocytopenia is mediated
by opsonization of platelets with antiplatelet antibody. After
obtaining and IND, 3G8 was infused into 4 patients with
refractory ITP all of whom had platelet counts consistently less
than 10,000/ul and significant clinical bleeding. Three of 4
patients demonstrated substantial acute platelet increases to
levels of 34,000/ul, 80,000/ul and 300,000/ul; one patient did not
respond. Surprisingly, the 3 patients with acute responses also all
had long-term benefits lasting months. Two patients continue to
maintain adequate platelet counts without any therapy 3 and 10
months after 3G8, the 3rd patient regained responsiveness to
IVGG and now requires IVGG treatment only every 5 weeks.
Serial opsonized red cell clearances indicated that the acute
effects were due to MPS FcR blockade. However the longterm
effects could be caused by either prolonged MPS FcR blockade
and/or by decreased levels of antiplatelet antibody. MPS FcR
function will be studied by serial opsonized red cell clearances.
The mechanism of this effect will be explored by studying
antiidiotypic and antiantiidiotypic antibody levels. Antiidiotypes
were detected in less than 2 weeks in patient #1 and persisted.
Development of an antiantiidiotype could mimic the effect of 3G8
and create endogenous modulation of FcRp52-70 expression.
Alternatively serial study of antiplatelet antibodies might reveal
a decrease that could explain the longterm benefits. If seen , a
decrease might occur as a result of the transient ablation of
natural killer (NK) cells seen immediately following infusion of
3G8, since NK cells contribute to immunoregulation of
immunoglobulin production. 3G8 is a promising new therapy of
refractory ITP. Its use in these patients will allow study of FcR
immunodulation in autoimmune disease.
3G8是一种小鼠单克隆抗FC受体抗体
识别并阻止了FCRP52-70的活动位置,发现了一个FCR
在粒细胞,组织巨噬细胞和大颗粒上
淋巴细胞。 MPS FCR与另一种小鼠单克隆
抗FCR抗体(24G2)已显示可降低清除率
小鼠的免疫复合物。 我们在黑猩猩的研究表明
注入3G8的重量大大减慢了调子的清除率
红细胞。 静脉注射γ球蛋白(IVGG)的临床研究
已建议MPS FCR封锁可能是治疗的基础
自身免疫性血小板减少紫红色的反应,严重
介导深度血小板减少症的出血障碍
通过用抗血小板抗体的血小板调理。 后
获得并IND,将3G8注入4例患者
难治性iTP所有的血小板数量始终减少
超过10,000/UL和大量临床出血。 4中的三个
患者表现出大量急性血小板增加到
34,000/UL,80,000/UL和300,000/UL的水平;一个患者没有
回应。 令人惊讶的是,3例急性反应的患者也
长期福利持续了几个月。 两个患者继续
保持足够的血小板计数,没有任何疗法3和10
3G8后几个月,第三名患者恢复了对
IVGG和现在只需要每5周一次IVGG治疗。
串行打折的红细胞间隙表明急性
效果是由于MPS FCR封锁所致。 但是长期
效果可能是由长时间的MPS FCR封锁引起的
和/或抗血小板抗体的水平降低。 MPS FCR
功能将通过连续的红细胞间隙来研究。
通过研究将探索这种效果的机制
抗替代型和抗体型型抗体水平。 抗iDiotypes
在不到2周的患者中检测到,并持续存在。
抗替代型的开发可以模仿3G8的效果
并创建FCRP52-70表达的内源性调制。
替代地对抗血小板抗体的系列研究可能揭示
可以解释长期收益的减少。 如果看见,一个
减少可能是由于瞬时消融而发生的
自然杀手(NK)细胞在输注后立即看到
3G8,因为NK细胞有助于免疫调节
免疫球蛋白产生。 3G8是一种有希望的新疗法
难治性ITP。 它在这些患者中的使用将允许研究FCR
自身免疫性疾病的免疫调节。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES B BUSSEL其他文献
JAMES B BUSSEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES B BUSSEL', 18)}}的其他基金
MONOCLONAL ANTI FCR ANTIBODY TREATMENT OF REFRACTORY ITP
抗FCR单克隆抗体治疗难治性ITP
- 批准号:
3354831 - 财政年份:1987
- 资助金额:
$ 12.53万 - 项目类别:
MONOCLONAL ANTI FCR ANTIBODY TREATMENT OF REFRACTORY ITP
抗FCR单克隆抗体治疗难治性ITP
- 批准号:
3354830 - 财政年份:1987
- 资助金额:
$ 12.53万 - 项目类别:
相似国自然基金
Tfh细胞调节自身抗体形成在溃疡性结肠炎体液免疫应答中的作用
- 批准号:81170361
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
胞内化抗体介导的HBcAg去功能化抑制HBV核壳体形成的机制研究
- 批准号:81070335
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
老年性和致病性II型胶原位点自身抗体形成机理探讨
- 批准号:39870857
- 批准年份:1998
- 资助金额:11.0 万元
- 项目类别:面上项目
相似海外基金
IgE受容体の架橋形成を示す特異IgE抗体の検出に基づく薬剤アレルギー検査法の開発
开发基于检测表明 IgE 受体交联的特异性 IgE 抗体的药物过敏测试方法
- 批准号:
24H02636 - 财政年份:2024
- 资助金额:
$ 12.53万 - 项目类别:
Grant-in-Aid for Encouragement of Scientists
抗原提示細胞に着目したCrohn病の病態形成におけるパターン認識受容体の解析
以抗原呈递细胞为中心分析克罗恩病发病机制中的模式识别受体
- 批准号:
22K15421 - 财政年份:2022
- 资助金额:
$ 12.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of new Type I allergy test based on the detection of IgE receptor cross-linking by the allergen
基于过敏原 IgE 受体交联检测的新型 I 型过敏测试的开发
- 批准号:
20K08774 - 财政年份:2020
- 资助金额:
$ 12.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ドラッグリポジショニングによるペルテス病の新規治療法の開発
利用药物重新定位开发治疗佩尔特斯病的新疗法
- 批准号:
19K09573 - 财政年份:2019
- 资助金额:
$ 12.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elongation of half-life time of vitamin D receptor ligands: acquisition of metabolic resistance and development of selective inhibitors against inactivation enzyme of vitamin D
延长维生素D受体配体的半衰期:获得代谢抗性并开发针对维生素D失活酶的选择性抑制剂
- 批准号:
18K06556 - 财政年份:2018
- 资助金额:
$ 12.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)